BioCentury
ARTICLE | Tools & Techniques

Optimata's virtual patients

November 17, 2003 8:00 AM UTC

Thrombopoietin was a hot molecule a few years ago, when a number of companies hoped to develop it to treat thrombocytopenia. They all ultimately dropped it due to immunogenicity problems. Now Optimata Ltd. has shown that it is possible to develop a non-immunogenic regimen simply by cutting the dose and giving it more frequently.

But the company's goal wasn't to revive TPO. Instead, Optimata wanted to show that it could develop an effective and safe regimen in silico and validate it in vivo...